ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO636

C-PAM, a Novel Iron Oxide-based Oral Drug, Efficiently Lowers Serum PI

Session Information

  • Pharmacology
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 1700 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Wagner, Susanne E., Wagner MSL Management, Mahlow, Germany
  • Schnorr, Jörg, Charité - Universitätsmedizin Berlin, Berlin, Germany
  • Ebert, Monika, Charité - Universitätsmedizin Berlin, Berlin, Germany
  • Stolzenburg, Nicola, Charité - Universitätsmedizin Berlin, Berlin, Germany
  • Taupitz, Matthias, Charité - Universitätsmedizin Berlin, Berlin, Germany

C-PAM is a novel compound designed for use as a serum Pi-lowering oral drug. It is composed of iron (Fe) oxide nanoparticles with a maghemite structure, mannitol, inulin, and Arabic gum. In previous analytical tests, C-PAM had a superior Pi-binding capacity compared to major approved Pi-binders. The hypothesis of this experimental in vivo study is that C-PAM more efficiently lowers serum Pi compared to those Pi-binders.


Healthy male Sprague-Dawley rats with a starting weight of 250 g were treated with drug co-feeding for 4 weeks (n=8 rats per group). C-PAM was added to Altromin standard 1320 diet (containing 0.6 wt% free adsorbable Pi) at 0.125, 0.25, and 0.5 wt% Fe. For comparison, three groups received Fosrenol® at 0.25 wt% La, Renvela® at 0.5 wt% sevelamer carbonate, and Velphoro® at 0.25 wt% Fe. As controls, one group received standard diet only and one group the carbohydrate components of C-PAM (mannitol, inulin, Arabic gum) at 2.0 wt%. Blood was sampled at the end of the 4-week study period and analyzed for serum Pi and standard parameters of hematology and clinical chemistry. For histopathology, HE and iron stains of liver, spleen, heart, lung, kidney, stomach, duodenum, jejunum, ileum, colon, and intestinal lymph nodes were assessed. Student's t-test was used for statistical analysis.


At all doses investigated, C-PAM reduced serum Pi significantly (0.125 wt%: p <.05, 0.25 and 0.5 wt%: p <.01). None of the other products tested or the carbohydrate components of C-PAM had a significant serum Pi lowering effect (figure). For C-PAM, except serum Pi, there was no effect on hematology and clinical chemistry parameters. No histopathologic changes were observed.


Even at a low dose, C-PAM effectively reduces serum Pi in healthy rats and thus is superior to three major approved products.

In vivo efficacy of C-PAM in lowering serum Pi at three different doses compared with three approved products, the carbohydrate components of C-PAM only, and with a control group (*p<.05; **p<.01).


  • Government Support - Non-U.S.